Stada CEO & CFO Resign; Rumors Circle Of A New Takeover bid
Executive Summary
Stada's top brass have quit following rumors earlier this week of a fresh takeover bid for the generic company from equity groups Bain and Cinven; ex-Boehringer executive Tjeenk Willink has been named incoming CEO.
You may also be interested in...
Deal Watch: Entasis, GARDP Partner On Novel Antibiotic For Drug-Resistant Gonorrhea
Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.
The End Of Generics Mergers? Too Much Effort, No Reward!
There has been $150bn worth of merger and acquisition activity since 2012 in the generic medicines arena, yet the sector is more fragmented than it was five years ago. CEOs and analysts from the generics sector believe that investor-propelled moves towards greater consolidation have been thwarted by the market agility of smaller companies. And now the cost of M&A has burdened major generics firms with debt.
Acquired Stada To Act As 'Core' For Future Bain and Cinven Bolt-Ons
Cinven and Bain seem likely to use German generics maker Stada as a nucleus around which to add smaller acquisitions, mostly in Europe, for an eventual exit by the private equity firms.